Jump down to…
When a drug interacts with a target, it leaves a trail of mediators like footprints in snow. If this trail does not accord with prevailing dogma on the drug’s mechanism of action, then we must consider the possibility that current teachings are flawed or untenable. Taken together this may suggest the existence of a mechanism of action about which we know nothing. By exposing this trail CEME has the power to …
McCormack Pharma’s customised association rules learning algorithm reveals a previously-unknown relationship between dexrazoxane and poly(ADP-ribose) (PAR) polymer. This previously-unknown relationship explains both acute and long-term cardioprotection in patients receiving anthracyclines, and provides exciting prospects for probing real world big data.
For the first time in over three decades, Dr McCormack openly discusses the methods that represent the basis for CEME’s success as the only purpose-built system for value-differentiation. Notably, he shows how he successfully built one of the earliest examples of an association rules learning algorithm as a means to overcome the challenges presented by text mining.
Further discussion, including a Powerpoint presentation, explaining how McCormack’s proprietary CEME method of data analysis works.
McCormack Pharma’s CEME models important differences between ACE inhibitors in their capacity to target the atherosclerosis plaque macrophage.
New teachings suggest that free fatty acid levels should be monitored or routinely lowered in patients receiving clopidogrel
An important announcement about the publication of McCormack’s report on the mechanism of clopidogrel resistance.
McCormack Pharma’s announcement on a breakthrough discovery on clopidogrel resistance clears the newswire and reaches a worldwide audience.
McCormack Pharma announces that Baltimore-based organisation eReleases has been recruited to handle the distribution of the Company’s press releases, further enhancing McCormack’s new online presence.
“Real world outcomes are more deterministic than random”, comments Dr Keith McCormack, founder and Research Director of McCormack Pharma, adding that… “So we need to understand what kind of world made these data.”
Using customized relational databases with the capacity to rapidly mine data and identify previously-unknown relationships, McCormack Pharma identifies free fatty acids as the final arbiter in determining the magnitude of clopidogrel resistance.
A landmark discovery by McCormack Pharma provides a new insight into why some patient subgroups are at increased risk of showing resistance to the popular anti-platelet drug clopidogrel (Plavix). Excitingly, the initial CEME outcomes provide evidence for the existence of a surprising relationship between a circulating marker that is typically elevated within discrete subpopulations of patients, and clopidogrel’s target, the P2Y12 platelet receptor.